VBIV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	163 502
Average Volume	451 452
Market Cap	18.02M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-0.170 ) 2024-05-20
Last Dividend	$0.250 ( 2012-04-02 )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.00900 (1.41%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-27	Dewilde Michel	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Braga Damian	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Baxter Jeff	Buy	70 000	Option (Right to Buy Common Shares)
2023-07-27	Cordeiro Joanne	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Beattie Nell	Buy	52 500	Option (Right to Buy Common Shares)

INSIDER POWER
-68.20
Last 96 transactions
Buy: 56 847 323 \| Sell: 16 390 901

Volume Correlation

Long: -0.26 (neutral)

Short: 0.32 (neutral)

Signal:(52.667) Neutral

VBI Vaccines Inc Correlation

10 Most Positive Correlations
KRON	0.879
VTSI	0.868
RUBY	0.866
ALVR	0.862
ICCC	0.849
PSTV	0.84
LSBK	0.828
GREE	0.827
POWW	0.827
PAIC	0.826

10 Most Negative Correlations
SHSP	-0.85
NETE	-0.84
BOCH	-0.832
BNIXU	-0.823
RAVN	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

VBI Vaccines Inc Correlation - Currency/Commodity

-0.15
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.54
( weak negative )

0.39
( neutral )

VBI Vaccines Inc Financials

Annual	2022
Revenue:	$1.08M
Gross Profit:	$-10.19M (-942.14 %)
EPS:	$-16.37

Q3	2023
Revenue:	$6.62M
Gross Profit:	$4.10M (61.88 %)
EPS:	$-0.970

Q2	2023
Revenue:	$720 000
Gross Profit:	$-2.76M (-383.75 %)
EPS:	$-5.18

Q1	2023
Revenue:	$485 000
Gross Profit:	$-3.07M (-633.81 %)
EPS:	$-4.35

Financial Reports:

No articles found.

VBI Vaccines Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

VBI Vaccines Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.250	2003-12-18
Last Dividend	$0.250	2012-04-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.23	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2027-05-31)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.23

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	$0.250	14.60%
2004	$0	0.00%
2005	$0	0.00%
2006	$0.750	16.50%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0.250	0.02%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-15.04	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.212	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.54	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.650	0.800	-1.752	-1.402	[1 - 3]
quickRatioTTM	0.464	0.800	-1.977	-1.582	[0.8 - 2.5]
cashRatioTTM	0.459	1.500	8.56	10.00	[0.2 - 2]
debtRatioTTM	0.513	-1.500	1.446	-2.17	[0 - 0.6]
interestCoverageTTM	-20.71	1.000	-8.78	-8.78	[3 - 30]
operatingCashFlowPerShareTTM	-3.21	2.00	-1.069	-2.14	[0 - 30]
freeCashFlowPerShareTTM	-3.31	2.00	-1.654	-3.31	[0 - 20]
debtEquityRatioTTM	2.60	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	-0.588	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-10.83	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.312	1.000	-8.40	-8.40	[0.2 - 2]
assetTurnoverTTM	0.0806	0.800	-2.80	-2.24	[0.5 - 2]
Total Score				-5.82

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.111	1.000	-0.112	0	[1 - 100]
returnOnEquityTTM	-3.54	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-3.31	2.00	-1.103	-3.31	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.21	2.00	-1.069	-2.14	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00148	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-8.36	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.94

VBI Vaccines Inc

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.